ALS Unit at the University Hospital La Paz – Carlos III. Madrid

The ALS Unit of the Hospital Carlos III in Madrid was created by Dr. Jesús Mora in 1990, being the first ALS Unit in Spain. In 2014 this Hospital joined the University Hospital La Paz and since then, both constitute a single institution.

In May 2018 the IMELA (ALS Institute of Madrid) was created with the aim of coordinate the ALS care in the region.

This ALS unit combines the diagnostic and multidisciplinary care for ALS patients with the clinical research focused on cognitive impairment assessment by scales validation and cognitive evoked potentials, quality of life studies, biomarkers and clinical trials with experimental therapies.

Comprehensive multidisciplinary care is provided by a team of neurologists, pychologists and nurses supported by neumologists, nutritionists and palliative care specialists in Hospital or home based. The Rehabilitation team provides motor, respiratory and speech therapies.

The Unit serves to ALS patients living in the Madrid Autonomous Community but also to many patients from other regions of the country. About three hundred patients are usually under treatment.

ALS Unit at the University Hospital La Paz – Carlos III. Madrid
Foundation year

1990

Director

Dra. Delia Chaverri, Dr. Jesús S. Mora (1990-2016)

Principal investigator

Dra. Delia Chaverri

Contact information
Address

Hospital Carlos III-HULP
Sinesio Delgado, 10.
28029, Madrid
Spain

Contact

Dra. Delia Chaverri

Phone

+34 914532500

Email ela.hciii@salud.madrid.org
Website Visit the website

Publications

Restricted information

Serving population
Serving population

2.000.000

Patient resources
Population based register

No

Clinic based register

Yes

Geographically matched controls

No

Banks

There are no banks for this centre

Research activities
Clinical management research

Yes

Neuro epidemiology

No

Neuro physiology

No

Neuro imaging

No

Neuro psychology

Yes

Neuro pathology

No

Genomics

No

Transcriptomics

Yes

Metabolomics

Yes

Clinical Trials - Industry sponsored

Name Type Patients
ORARIALS-01. Arimoclomol 2019- Phase III
AB10015. Masitinib 2013-2017. NCT02588677 Phase II-III 106
BENEFIT-ALS. Tirasemtiv 2013-2014. NCT01709149 Phase II 24
EMPOWER. Dexpramipexole 2011-2013. NCT01281189 Phase II 37
TRO 19622.Olesoxime 2009-2011. NCT00868166 Phase II-III 67
ALS-TAL-201 Talampanel 2008-2010. NCT00696332. Phase II 52
ONO 2506PO. 2004-2006 NCT00403104 Phase II 28
EFC1923 Xaliprodem 1997-1999 Phase II 79
RILUZOLE 1993-1995 Phase III 36
BCAA (branched chain Aminoacids) 1990-1992 .Ajinomoto Ltd Phase II 35

Clinical Trials - Investigator initiated

There are no clinical trials for this centre